Cargando…
Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
This cross-sectional study analyzes data on aggregate utilization and aggregate spending by patients and by pharmacy benefit managers to pharmacies for every brand-name drug prescription dispensed to all fully insured patients and some self-insured patients with commercial insurance in Massachusetts...
Autores principales: | Aaron, Micah B., Sinaiko, Anna D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994951/ https://www.ncbi.nlm.nih.gov/pubmed/33764422 http://dx.doi.org/10.1001/jamanetworkopen.2021.3252 |
Ejemplares similares
-
Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022) -
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021) -
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023) -
Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study
por: Liu, Michael, et al.
Publicado: (2020) -
The effect of the Affordable Care Act on patient out-of-pocket cost and use of preventive cancer screenings in Massachusetts
por: Steenland, Maria, et al.
Publicado: (2019)